Holen Sie sich die Stockscreener-App
73.29
2.35%
-1.82
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
TD Cowen Raises Price Target for HALO to $90.00, Maintains Buy Rating | HALO Stock News - GuruFocus
Halozyme Partners with Takeda to Develop and Commercialize Vedolizumab - Contract Pharma
Halozyme Allows Takeda To Access Its ENHANZE Drug Delivery Technology For Use With Vedolizumab - Nasdaq
Takeda (TAK) Partners with Halozyme for Enhanced Drug Delivery - GuruFocus
Halozyme signs licensing deal with Takeda for vedolizumab delivery tech By Investing.com - Investing.com Australia
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE® - PR Newswire
Why Halozyme Therapeutics Inc. stock remains undervaluedLarge Cap Stability Picks & Low Cost Capital Trading - ulpravda.ru
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Obesity Partnership With Skye Bioscience - Yahoo Finance
Insider Sell: Bernadette Connaughton Sells 2,000 Shares of Halozyme Therapeutics Inc (HALO) - GuruFocus
Is Halozyme Therapeutics Inc. (RV7) stock undervalued after correction2026 world cup usa national team round of 16 goalkeepers high defensive line knockout prediction expert opinion - ulpravda.ru
Halozyme and Skye partner on obesity drug delivery technology By Investing.com - Investing.com Nigeria
Skye Bioscience shares rise on Halozyme partnership to advance obesity treatment - MSN
Halozyme Therapeutics, Skye Bioscience Collaborate to Evaluate Nimacimab for Obesity Treatment - MarketScreener
Skye Bioscience Licenses Halozyme’s ENHANZE Drug Delivery Technology - Contract Pharma
Skye Bioscience stock jumps after Halozyme collaboration for obesity drug By Investing.com - Investing.com Nigeria
Skye Bioscience stock jumps after Halozyme collaboration for obesity drug - Investing.com
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Robust Revenue Growth and Strategic Partnerships Fuel Investor Optimism - DirectorsTalk Interviews
Halozyme Therapeutics (HALO) Partners with Skye Bioscience for I - GuruFocus
Halozyme (HALO) Partners with Skye Bioscience for Obesity Treatm - GuruFocus
Halozyme and Skye partner on obesity drug delivery technology - Investing.com
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity - The Manila Times
Halozyme Therapeutics (FRA:RV7) EV-to-OCF : 14.00 (As of Jan. 04, 2026) - GuruFocus
Cwm LLC Acquires 22,813 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Arbor Investment Advisors LLC Invests $1.32 Million in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Valuation Update: Why Halozyme Therapeutics Inc RV7 stock is a must watch tickerJuly 2025 Rallies & Low Drawdown Trading Techniques - moha.gov.vn
Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025 - The Globe and Mail
How Halozyme Therapeutics Inc. (HALO) Affects Rotational Strategy Timing - Stock Traders Daily
Here's What Analysts Think About Halozyme Therapeutics (HALO) - Finviz
Here’s What Analysts Think About Halozyme Therapeutics (HALO) - Insider Monkey
Market Still Lacking Some Conviction On Halozyme Therapeutics, Inc. (NASDAQ:HALO) - 富途牛牛
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of "Hold" by Brokerages - MarketBeat
Zacks Research Brokers Increase Earnings Estimates for HALO - MarketBeat
Shaker Investments LLC OH Decreases Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Voya Investment Management LLC Has $3.39 Million Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Pacer Advisors Inc. Acquires 456,649 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Osaic Holdings Inc. Grows Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Hedge Fund and Insider Trading News: Steve Cohen, Ray Dalio, Warren Buffett, Alan Howard, Scott Bessent, Saba Capital Management, Halozyme Therapeutics Inc (HALO), Epsilon Energy Ltd (EPSN), and More - Insider Monkey
Halozyme Therapeutics CEO sells $1.14 million in stock - Investing.com
Halozyme Therapeutics Stock Sees Relative Strength Rating - Investor's Business Daily
27,468 Shares in Halozyme Therapeutics, Inc. $HALO Acquired by Monument Capital Management - MarketBeat
Halozyme Therapeutics (HALO): Valuation Check After FDA Win and Patent Court Victory - Yahoo Finance
Halozyme Therapeutics (HALO) Is Up 7.4% After New ENHANZE NSCLC Win And Patent InjunctionWhat's Changed - Yahoo Finance
Does Halozyme Still Offer Value After a 44.5% Surge and Strong DCF Upside? - Sahm
Is Halozyme Still Attractively Priced After Its Strong 2025 Share Price Rally? - Yahoo Finance
EBITDA per share of Halozyme Therapeutics, Inc. – TRADEGATE:RV7 - TradingView — Track All Markets
Halozyme Therapeutics (BIT:1HALO) Price Target Decreased by 13.37% to 59.51 - Nasdaq
Halozyme Therapeutics (MEX:HALO) EV-to-OCF : 13.06 (As of Dec. 23, 2025) - GuruFocus
Halozyme Therapeutics (STU:RV7) EV-to-OCF : 13.50 (As of Dec. 22, 2025) - GuruFocus
Why Halozyme Therapeutics (HALO) Is Up 8.3% After FDA Nod And Patent Win In Lung Cancer - Sahm
Congress Asset Management Co. Cuts Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
(HALO) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Market Fear: Is Halozyme Therapeutics Inc. (RV7) stock undervalued after correctionJuly 2025 Opening Moves & Low Volatility Stock Suggestions - ulpravda.ru
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) COO Sells 4,263 Shares of Stock - MarketBeat
HALO (Halozyme Therapeutics) EV-to-OCF : 14.29 (As of Dec. 20, 2025) - GuruFocus
COO Caudill Acquires 5,063 Of Halozyme Therapeutics Inc [HALO] - TradingView — Track All Markets
HC Wainwright & Co. Reiterates Halozyme Therapeutics (HALO) Buy Recommendation - Nasdaq
Is Halozyme Therapeutics Inc. stock vulnerable to regulatory risksWeekly Stock Summary & Community Trade Idea Sharing - Улправда
Breakouts Watch: Why Halozyme Therapeutics Inc. stock could see breakout soonJuly 2025 Levels & Weekly Breakout Opportunity Watchlist - Улправда
Halozyme Therapeutics Stock (HALO) Opinions on FDA Approval and Legal Win - Quiver Quantitative
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance
5.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):